Apple, Samsung face onslaught at mobile fair






BARCELONA - Chinese handset makers will lead an onslaught on smartphone titans Samsung and Apple when the world's biggest mobile fair opens on Monday in Barcelona, Spain.

Offering big-screen, slick, slim smartphones at lower prices, Chinese manufacturers Huawei, ZTE and Lenovo will leverage the Mobile World Congress to chip away at the mighty duopoly, analysts say.

The handset battle is part of a broader revolt against a handful of companies with a stranglehold on the booming industry's handsets, operating systems and microchips, they say.

Apple, as usual, is steering clear of the February 25-28 congress that draws 1,500 exhibitors to this Mediterranean city in northeastern Spain, and Samsung is not expected to launch its next big offer, the Galaxy S4, until some time after the show.

That may leave the field clear for rivals to tout their ambitions for a slice of the smartphone market, which is set to grow to a record one billion handset shipments in 2013, according to a forecast by global consultancy Deloitte.

"I think we will see challengers trying to make noise at the Mobile World Congress this year," said Ian Fogg, London-based senior mobile analyst at research house IHS.

New players face a daunting task, though.

Samsung and Apple accounted for more than half of all smartphone sales in the final quarter of 2012 -- 29.0 percent for Samsung and 22.1 percent for Apple -- according to research firm Strategy Analytics.

Behind Samsung and Apple, however, Chinese firms held the third, fourth and fifth spots -- with 5.3 percent for Huawei, 4.7 percent for ZTE and 4.4 percent for Lenovo.

Demand for smartphones in developing countries could give Chinese firms a bigger opening, said Magnus Rehle, senior partner at telecommunications management consultancy group Greenwich Consulting.

"Hundreds of millions of Africans and Indians and Asians want to have a smartphone and so far the blocking point has been the price," said Rehle, speaking from Ghana.

Now the Chinese firms were offering attractive smartphones at lower prices, he said.

"I think they will be quite successful in grabbing the new market outside of Europe and the US, and that is where the growth is," Rehle said.

An even mightier duopoly holds sway over the operating system software that makes the smartphones work.

Google's Android ran 69 percent of all handsets sold last year and Apple's iOS 22 percent, said a study by independent analytical house Canalys.

Yet they face challengers, too, including Mozilla's new open-sourced Firefox OS, backed by an array of mobile phone operators.

Microsoft's new Windows Mobile operating system is struggling, however.

"The number of apps that is available is one thing that is blocking Windows from being successful," Rehle said.

"They have had problems and everybody is hoping this will change because the duopoly is maybe not good for the market."

Firefox could face similar difficulties, he predicted.

A battle has broken out, too, over the processor chips that run the smartphones.

Santa Clara, California-based Intel is offering new high-performance chips to break its way into smartphones, of which almost all now use chip technology licensed by ARM, based in Cambridge, England.

Chinese group Lenovo, for example, is launching a new handset, the IdeaPhone K900, just 6.9mm thick with a 5.5-inch high definition screen, which contains an Intel Clover Trail processor.

The potential rewards for Intel could be rich: the market in processor chips for smartphone applications was worth nearly seven billion euros (US$9 billion) last year, said Francis Sideco, communications technology analyst at IHS.

Despite robust growth in smartphones and tablet sales, however, the mobile industry still faces a major challenge moving customers over to new ultrafast fourth generation, or 4G, networks, which can offer speeds similar to a fixed fibre-optic connection.

"There are 3G networks in many parts of the world like in Sweden that have been overcrowded and then you have parallel 4G networks that are almost empty," said Greenwich Consulting's Rehle.

Network operators need to convince their customers to pay a little more for the faster speeds, he said, pointing to videos as the "killer application" to lure people to the system over the longer term.

If the operators succeed, they can make more money and invest in greater capacity, the analyst said.

"Otherwise, they will have problems."

- AFP/ir



Read More..

BJP working on improving strength in South, NE, Rajnath Singh says

NEW DELHI: BJP president Rajnath Singh has said his party will focus on improving its electoral prospects in the southern states and the North-East in the next general elections as part of the NDA's efforts to win more seats and wrest power from the Congress-led UPA coalition.

"We have had our government in Karnataka and we will try to retain the number of seats we had won last time. Our performance in Andhra Pradesh and Tamil Nadu can improve from what it was last time and efforts are on for that. As for the northeast, four MPs won from there last time and I hope that the number will not decrease," Singh told PTI in an interview.

He was replying to a question on the NDA's prospects in the south and the northeast in the next general elections.

Many feel the party's performance in Karnataka may go down in the Lok Sabha polls due to the constant infighting in the BJP-led government in the state. This has dented the image of the party.

Singh accepted that the exit of former Karnataka chief minister B S Yeddyurappa from BJP to form a new party may affect his party's performance.

"We cannot determine the quantum of loss, but even if some loss has taken place we would try to regain it," he said.

Singh maintained that in the 2014 general elections his party would not just highlight the failures of the Congress-led UPA government but also emphasize on programmes that it will implement if voted to power.

"We will tell the people what all we will do if we form government at the Centre," he said.

Singh said the Congress-led government has failed on every front. "They have failed on the economic, security and diplomatic front. But we won't contest elections on the basis of this government's failure, not just negatives but we will fight the elections on political issues also," he said.

He maintained that there is a need for BJP to make its organizational network "more active and effective".

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Las Vegas Strip Shooting Suspect ID'd












Las Vegas police identified a suspect today in a shooting on the strip that caused a Maserati to hit a taxi and burst into flames, killing three people.


Ammar Harris, 26, has been named a suspect in the Thursday skirmish that killed three people, including rapper Kenny Clutch.


The altercation between Harris and Clutch, 27, whose legal name was Kenneth Cherry Jr., is believed to have originated in the valet area of a Las Vegas hotel, police said.


Police said Harris fired several rounds into a Maserati that was being driven by Cherry as both vehicles continued northbound on glitzy Las Vegas Boulevard.


The rapper's expensive sports car careened out of control after he was shot, slamming into several cars, including a taxi. The impact caused the cab to burst into flames, killing the driver, Michael Boldon and a female passenger. Witnesses said it looked like the car exploded.


"He was a number one guy," Carolyn Jean Trimble, Boldon's sister, told ABC News.








California Man's Carjacking Spree Takes 3 Victims Watch Video









Chicago Teen Killed Day of Obama's Anti-Violence Speech Watch Video









Dallas Courthouse Shooting Manhunt Intensify Watch Video





"I looked out my window and I could see one vehicle down here on the corner of the intersection totally engulfed in flames," witness John Lamb told ABC News.


Boldon, 62, and his passenger, who has not yet been identified, were both killed, as was Clutch.


Timble said her brother loved driving his taxi around Vegas.


"He came to live with me in Las Vegas last year to help take care of our mother, and the first day he got here he said, 'I have to get a job.' The second day, I came home from work, and he said he got a job," she recalled.


"He says, 'You'll never guess what it is,' and I said, 'what,' and he said, 'taxi cab driver,' and we both fell out laughing," Trimble said. "He loved that job. He never complained. He'd come home and tell me stories about what happened, who he picked up."


Boldon was a single father who raised a 36-year-old son and was a new grandfather. His grandson was named after him, Trimble said.


"Of all the people to take from this earth," she said. "But I guess the Lord needed him."


A passenger in the Maserati was hit and sustained only a minor injury to his arm. Clutch died at University Medical Center.


His father, Kenneth Cherry Sr., expressed his grief for the loss of his son while speaking with ABC News.


"This is something you never really, really ever want to experience as a parent, to lose a child before you go," he said.


Harris is described as 5-foot-11 and 180 pounds. Anyone with information is asked to contact the Las Vegas Metro Police Department's homicide division.



Read More..

Tennis: Nishikori beats Cilic to reach Memphis semis






MEMPHIS, Tennessee - Fifth-seeded Kei Nishikori of Japan cruised past top-seeded Marin Cilic 6-4, 6-2 on Friday to reach the semi-finals of the US National Indoor Tennis Championships.

Croatia's Cilic had saved three match points in his previous match against Igor Sijsling, but could not find the answer against Nishikori, who had just four aces compared to a dozen for Cilic but won 69 percent of points on his serve.

"I was dominating with my serve," said the 23-year-old Nishikori, who also reached the semi-finals in Brisbane in January but retired from that match against Andy Murray with a knee injury.

Since then, he has reached the fourth round of the Australian Open.

"It's getting better every match... little by little," Nishikori said of his game.

He next faces Australian Marinko Matosevic, a 6-7 (6/8), 6-2, 6-4 winner over seventh-seeded Alexandr Dolgopolov of Ukraine.

Nishikori won their only prior meeting at Brisbane earlier this year.

The other men's semi-final in this combined ATP and WTA event will pit Spain's Feliciano Lopez against Uzbekistan's Denis Istoman.

Lopez defeated US wildcard Jack Sock 6-4, 6-3, and Istoman was a 6-4, 7-6 (7/5) winner over Michael Russell of the United States.

In women's action, big-hitting Sabine Lisicki of Germany set up a title showdown with Marina Erakovic.

Lisicki, the third seed, fell behind in each set but dug deep for a 7-5, 7-5 semi-final win over seventh-seeded Magdalena Rybarikova. She will be vying for a fourth career WTA title.

New Zealand's Erakovic defeated Stefanie Voegele of Switzerland 6-2, 6-4 to earn a shot at a first WTA title. She has two runner-up finishes on her resume, including in Memphis last year.

- AFP/ir



Read More..

59-hour countdown for Isro's PSLV-C20 begins

CHENNAI: The 59-hour countdown for the February 25 launch of Polar Satellite Launch Vehicle to put into orbit seven satellites, including Indo-French spacecraft SARAL, commenced at 6.56am today at the Satish Dhawan Space Centre in the spaceport of Sriharikota.

The Launch Authorisation Board earlier cleared the launch schedule for February 25 at 5.56 PM from the first launch pad in Sriharikota, about 90 kms from here, Isro sources said.

PSLV-C20, the 23rd PSLV Mission of Isro, would put the 400 kg Indo-French satellite and six others into orbit.

SARAL refers to Satellite with ARgos and ALtika. The French space agency CNES has developed ARgos and ALtikameter for analysing the ocean.

The rehearsal launch of PSLV - C20 with the primary satellite SARAL and six other foreign satellites has been completed satisfactorily, the sources said.

The other six auxiliary payloads are - two each from Canada, Austria and one each from Denmark and the United Kingdom.

President Pranab Mukherjee is likely to witness the launch along with Andhra Pradesh chief minister Kiran Kumar Reddy.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Cyberattacks Bring Attention to Security Reform











Recent accusations of a large-scale cyber crime effort by the Chinese government left many wondering what immediate steps the president and Congress are taking to prevent these attacks from happening again.


On Wednesday, the White House released the administration's Strategy on Mitigating the Theft of U.S. Trade Secrets as a follow-up to the president's executive order. The strategy did not outwardly mention China, but it implied U.S. government awareness of the problem.


"We are taking a whole of government approach to stop the theft of trade secrets by foreign competitors or foreign governments by any means -- cyber or otherwise," U.S. Intellectual Property Enforcement Coordinator Victoria Espinel said in a White House statement.


As of now, the administration's strategy is the first direct step in addressing cybersecurity, but in order for change to happen Congress needs to be involved. So far, the Cyber Intelligence Sharing and Protection Act (CISPA) is the most notable Congressional legislation addressing the problem, despite its past controversy.


Last April, CISPA was introduced by House Intelligence Committee Chairman Mike Rogers, R-Mich., and Rep. Dutch Ruppersberger, D-Md. The act would allow private companies with consumer information to voluntarily share those details with the NSA and the DOD in order to combat cyber attacks.






Peter Parks/AFP/Getty Images







The companies would be protected from any liabilities if the information was somehow mishandled. This portion of the act sounded alarm bells for CISPA's opponents, like the ACLU, which worried that this provision would incentivize companies to share individuals' information with disregard.


CISPA passed in the House of Representatives, despite a veto threat from the White House stemming from similar privacy concerns. The bill then died in the Senate.


This year, CISPA was reintroduced the day after the State of the Union address during which the president declared an executive order targeting similar security concerns from a government standpoint.


In contrast to CISPA, the executive order would be initiated on the end of the government, and federal agencies would share relevant information regarding threats with private industries, rather than asking businesses to supply data details. All information shared by the government would be unclassified.


At the core of both the executive order and CISPA, U.S. businesses and the government would be encouraged to work together to combat cyber threats. However, each option would clearly take a different route to collaboration. The difference seems minimal, but has been the subject of legislative debates between the president and Congress for almost a year, until now.


"My response to the president's executive order is very positive," Ruppersberger told ABC News. "[The president] brought up how important information sharing is [and] by addressing critical infrastructure, he took care of another hurdle that we do not have to deal with."


Addressing privacy roadblocks, CISPA backers said the sharing of private customer information with the government, as long as personal details are stripped, is not unprecedented.


"Think of what we do with HIPAA in the medical professions; [doctors do not need to know] the individual person, just the symptoms to diagnose a disease," Michigan Gov. John Engler testified at a House Intelligence Committee hearing in an attempt to put the problem into context.






Read More..

Wilmar International's Q4 net profit falls 4.7%






SINGAPORE: Wilmar International's net profit in the fourth quarter fell 4.7 per cent, weighed mainly by lower palm oil prices.

Fourth-quarter net profit was US$476.8 million (S$590 million), down from US$500 million recorded in the same period in 2011.

A decline in crude palm oil prices hit profits in the firm's plantations segment, which were down 23 per cent compared to the previous year.

Fourth-quarter revenue rose 0.9 per cent on year to US$11.6 billion (S$14.4 billion).

Wilmar International's chairman and CEO Kuok Khoon Hong said the Group remains positive on its long term prospects due to "good economic growth" in its main markets of China, India and Indonesia and robust business model.

Separately, Wilmar International and Noble Group also announced a joint venture to develop palm projects in Papua, Indonesia.

In a statement, the companies said Wilmar's subsidiary Newbloom will hold a 53.74 per cent equity stake in the venture while Noble unit Noble Plantations will own a 46.27 per cent stake.

The joint venture owns a majority interest in PT Henrison Inti Persada, which owns 22,953 hectares of land in Papua.

- CNA/ck



Read More..

Suspend question hour to discuss blasts: BJP

NEW DELHI: The Bharatiya Janata Party (BJP) Friday demanded that question hour be suspended in both houses to discuss the Hyderabad terror attack.

"We have asked for suspension of question hour and demanded discussion on the terror issue," BJP leader Prakash Javadekar told reporters outside parliament.

He said the country was united at this hour and party president Rajnath Singh had gone to Hyderabad to meet the victims.

"The government is failing in fight against terror and we will raise the matter in parliament," he said.

Sixteen people were killed and more than 100 injured in the twin bomb blasts that rocked Hyderabad Thursday evening.

Read More..